Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.

Montagut C, Argilés G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, Kopetz S, Lindsted T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sánchez-Martín FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A, Tabernero J.

JAMA Oncol. 2018 Feb 8:e175245. doi: 10.1001/jamaoncol.2017.5245. [Epub ahead of print]

PMID:
29423521
2.

Tumor Side as Model of Integrative Molecular Classification of Colorectal Cancer.

Dienstmann R.

Clin Cancer Res. 2017 Dec 21. doi: 10.1158/1078-0432.CCR-17-3477. [Epub ahead of print]

PMID:
29269378
3.

Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.

Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L, Murumägi A, Arjama M, Danielsen SA, Kryeziu K, Elez E, Tabernero J, Guinney J, Palmer HG, Nesbakken A, Kallioniemi O, Dienstmann R, Lothe RA.

Clin Cancer Res. 2018 Feb 15;24(4):794-806. doi: 10.1158/1078-0432.CCR-17-1234. Epub 2017 Dec 14.

PMID:
29242316
4.

Reply to the letter to the editor 'Including lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer' by Sciallero et al.

Dienstmann R, Guinney J.

Ann Oncol. 2017 Nov 1;28(11):2889-2890. doi: 10.1093/annonc/mdx415. No abstract available.

PMID:
29045507
5.

Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells.

Roumeliotis TI, Williams SP, Gonçalves E, Alsinet C, Del Castillo Velasco-Herrera M, Aben N, Ghavidel FZ, Michaut M, Schubert M, Price S, Wright JC, Yu L, Yang M, Dienstmann R, Guinney J, Beltrao P, Brazma A, Pardo M, Stegle O, Adams DJ, Wessels L, Saez-Rodriguez J, McDermott U, Choudhary JS.

Cell Rep. 2017 Aug 29;20(9):2201-2214. doi: 10.1016/j.celrep.2017.08.010.

6.

Cancer: A precision approach to tumour treatment.

Dienstmann R, Tabernero J.

Nature. 2017 Aug 3;548(7665):40-41. doi: 10.1038/nature23101. Epub 2017 Jul 19. No abstract available.

PMID:
28723897
7.

Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights.

Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J.

Mol Oncol. 2017 Sep;11(9):1263-1272. doi: 10.1002/1878-0261.12099. Epub 2017 Jul 20.

8.

Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology.

Garralda E, Dienstmann R, Tabernero J.

Am Soc Clin Oncol Educ Book. 2017;37:210-215. doi: 10.14694/EDBK_180460. Review.

9.

Personalizing Adjuvant Therapy for Stage II/III Colorectal Cancer.

McCleary NJ, Benson AB 3rd, Dienstmann R.

Am Soc Clin Oncol Educ Book. 2017;37:232-245. doi: 10.14694/EDBK_175660. Review.

10.

Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.

Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J.

Ann Oncol. 2017 May 1;28(5):1023-1031. doi: 10.1093/annonc/mdx052.

11.

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.

Grasselli J, Elez E, Caratù G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Viéitez JM, Paéz D, Falcó E, Lopez Lopez C, Aranda E, Jones F, Sikri V, Nuciforo P, Fasani R, Tabernero J, Montagut C, Azuara D, Dienstmann R, Salazar R, Vivancos A.

Ann Oncol. 2017 Jun 1;28(6):1294-1301. doi: 10.1093/annonc/mdx112.

PMID:
28368441
12.

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J.

Nat Rev Cancer. 2017 Mar 23;17(4):268. doi: 10.1038/nrc.2017.24. No abstract available.

PMID:
28332502
13.

CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer.

Griffith M, Spies NC, Krysiak K, McMichael JF, Coffman AC, Danos AM, Ainscough BJ, Ramirez CA, Rieke DT, Kujan L, Barnell EK, Wagner AH, Skidmore ZL, Wollam A, Liu CJ, Jones MR, Bilski RL, Lesurf R, Feng YY, Shah NM, Bonakdar M, Trani L, Matlock M, Ramu A, Campbell KM, Spies GC, Graubert AP, Gangavarapu K, Eldred JM, Larson DE, Walker JR, Good BM, Wu C, Su AI, Dienstmann R, Margolin AA, Tamborero D, Lopez-Bigas N, Jones SJ, Bose R, Spencer DH, Wartman LD, Wilson RK, Mardis ER, Griffith OL.

Nat Genet. 2017 Jan 31;49(2):170-174. doi: 10.1038/ng.3774. No abstract available.

14.

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J.

Nat Rev Cancer. 2017 Feb;17(2):79-92. doi: 10.1038/nrc.2016.126. Epub 2017 Jan 4. Review. Erratum in: Nat Rev Cancer. 2017 Mar 23;17 (4):268.

PMID:
28050011
15.

Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment.

Dienstmann R, Tabernero J.

Cancer J. 2016 May-Jun;22(3):149-55. doi: 10.1097/PPO.0000000000000191. Review.

PMID:
27341591
16.

Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.

Azuara D, Santos C, Lopez-Doriga A, Grasselli J, Nadal M, Sanjuan X, Marin F, Vidal J, Montal R, Moreno V, Bellosillo B, Argiles G, Elez E, Dienstmann R, Montagut C, Tabernero J, Capellá G, Salazar R.

Mol Cancer Ther. 2016 May;15(5):1106-12. doi: 10.1158/1535-7163.MCT-15-0820. Epub 2016 Apr 1.

17.

The consensus molecular subtypes of colorectal cancer.

Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S.

Nat Med. 2015 Nov;21(11):1350-6. doi: 10.1038/nm.3967. Epub 2015 Oct 12.

18.

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.

Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit JW, Stuyckens K, Chatterjee-Kishore M, Rodon J, Peddareddigari V, Luo FR, Soria JC.

J Clin Oncol. 2015 Oct 20;33(30):3401-8. doi: 10.1200/JCO.2014.60.7341. Epub 2015 Aug 31.

PMID:
26324363
19.

First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.

Dienstmann R, Lassen U, Cebon J, Desai J, Brown MP, Evers S, Su F, Zhang W, Boisserie F, Lestini B, Schostack K, Meresse V, Tabernero J.

Target Oncol. 2016 Apr;11(2):149-56. doi: 10.1007/s11523-015-0381-x.

PMID:
26310975
20.

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.

García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V.

Clin Cancer Res. 2015 Dec 15;21(24):5499-5510. doi: 10.1158/1078-0432.CCR-14-3091. Epub 2015 Aug 13. Erratum in: Clin Cancer Res. 2016 Aug 1;22(15):3982.

21.

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.

Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG.

Clin Cancer Res. 2016 Feb 1;22(3):644-56. doi: 10.1158/1078-0432.CCR-14-3081. Epub 2015 Jul 29.

22.

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.

Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR Jr, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J.

Clin Cancer Res. 2015 Jun 1;21(11):2462-70. doi: 10.1158/1078-0432.CCR-14-2412.

23.

Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.

Dienstmann R, Salazar R, Tabernero J.

Am Soc Clin Oncol Educ Book. 2015:e149-56. doi: 10.14694/EdBook_AM.2015.35.e149. Review.

24.

Heterogeneity of driver genes and therapeutic implications in colorectal cancer.

Dienstmann R, Cervantes A.

Ann Oncol. 2015 Aug;26(8):1523-5. doi: 10.1093/annonc/mdv229. Epub 2015 May 12. No abstract available.

PMID:
25969371
25.

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Roselló S, Tops BB, van der Post RS, Argilés G, Skartved NJ, Hansen UH, Hald R, Pedersen MW, Kragh M, Horak ID, Braun S, Van Cutsem E, Tolcher AW, Tabernero J.

Cancer Discov. 2015 Jun;5(6):598-609. doi: 10.1158/2159-8290.CD-14-1432. Epub 2015 May 11.

26.

Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients.

Dienstmann R, Salazar R, Tabernero J.

J Clin Oncol. 2015 Jun 1;33(16):1787-96. doi: 10.1200/JCO.2014.60.0213. Epub 2015 Apr 27. Review.

PMID:
25918287
27.

A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.

Mau-Sørensen M, Dittrich C, Dienstmann R, Lassen U, Büchler W, Martinius H, Tabernero J.

Cancer Chemother Pharmacol. 2015 May;75(5):1065-73. doi: 10.1007/s00280-015-2728-5. Epub 2015 Mar 27.

PMID:
25814216
28.

Genomic testing in colorectal cancer: how much is enough?

Dienstmann R, Salazar R, Tabernero J.

Oncology (Williston Park). 2015 Mar;29(3):186-8. No abstract available.

29.

Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors.

Dienstmann R, Jang IS, Bot B, Friend S, Guinney J.

Cancer Discov. 2015 Feb;5(2):118-23. doi: 10.1158/2159-8290.CD-14-1118.

30.
31.

Intrinsic cancer subtypes--next steps into personalized medicine.

Santos C, Sanz-Pamplona R, Nadal E, Grasselli J, Pernas S, Dienstmann R, Moreno V, Tabernero J, Salazar R.

Cell Oncol (Dordr). 2015 Feb;38(1):3-16. doi: 10.1007/s13402-014-0203-7. Epub 2015 Jan 14. Review.

PMID:
25586691
32.

Social interactomes for enabling research communities.

Guinney J, Dienstmann R, Ferté C, Friend S, McCormick F.

Cancer Discov. 2014 Nov;4(11):1265-8. doi: 10.1158/2159-8290.CD-14-0774.

33.

Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.

Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR.

Gastroenterology. 2015 Jan;148(1):88-99. doi: 10.1053/j.gastro.2014.09.041. Epub 2014 Oct 8.

34.

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.

Soria JC, DeBraud F, Bahleda R, Adamo B, Andre F, Dienstmann R, Delmonte A, Cereda R, Isaacson J, Litten J, Allen A, Dubois F, Saba C, Robert R, D'Incalci M, Zucchetti M, Camboni MG, Tabernero J.

Ann Oncol. 2014 Nov;25(11):2244-51. doi: 10.1093/annonc/mdu390. Epub 2014 Sep 5. Erratum in: Ann Oncol. 2015 Feb;26(2):445. Dientsmann, R [corrected to Dienstmann, R].

PMID:
25193991
35.

Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test.

Dienstmann R, Rodon J, Tabernero J.

Mol Oncol. 2015 May;9(5):940-50. doi: 10.1016/j.molonc.2014.06.014. Epub 2014 Jul 15. Review.

36.

The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning.

Dienstmann R, Salazar R, Tabernero J.

Am Soc Clin Oncol Educ Book. 2014:91-9. doi: 10.14694/EdBook_AM.2014.34.91. Review.

37.

TGR analysis in phase I clinical trials--letter.

Dienstmann R, Tabernero J.

Clin Cancer Res. 2014 May 1;20(9):2495-6. doi: 10.1158/1078-0432.CCR-13-3455. No abstract available.

38.

Standardized decision support in next generation sequencing reports of somatic cancer variants.

Dienstmann R, Dong F, Borger D, Dias-Santagata D, Ellisen LW, Le LP, Iafrate AJ.

Mol Oncol. 2014 Jul;8(5):859-73. doi: 10.1016/j.molonc.2014.03.021. Epub 2014 Apr 4. Review.

39.

Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.

Dienstmann R, Rodon J, Serra V, Tabernero J.

Mol Cancer Ther. 2014 May;13(5):1021-31. doi: 10.1158/1535-7163.MCT-13-0639. Epub 2014 Apr 18. Review.

40.

Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial.

Bines J, Dienstmann R, Obadia RM, Branco LG, Quintella DC, Castro TM, Camacho PG, Soares FA, Costa ME.

Ann Oncol. 2014 Apr;25(4):831-6. doi: 10.1093/annonc/mdu015. Epub 2014 Mar 10.

PMID:
24615412
41.

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.

Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J.

Ann Oncol. 2014 Mar;25(3):552-63. doi: 10.1093/annonc/mdt419. Epub 2013 Nov 20. Review.

42.

Genomic medicine frontier in human solid tumors: prospects and challenges.

Dienstmann R, Rodon J, Barretina J, Tabernero J.

J Clin Oncol. 2013 May 20;31(15):1874-84. doi: 10.1200/JCO.2012.45.2268. Epub 2013 Apr 15. Review.

PMID:
23589551
43.

Biomarker-driven patient selection for early clinical trials.

Dienstmann R, Rodon J, Tabernero J.

Curr Opin Oncol. 2013 May;25(3):305-12. doi: 10.1097/CCO.0b013e32835ff3cb. Review.

PMID:
23493192
44.

Development of PI3K inhibitors: lessons learned from early clinical trials.

Rodon J, Dienstmann R, Serra V, Tabernero J.

Nat Rev Clin Oncol. 2013 Mar;10(3):143-53. doi: 10.1038/nrclinonc.2013.10. Epub 2013 Feb 12. Review.

PMID:
23400000
45.

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

Dienstmann R, Serpico D, Rodon J, Saura C, Macarulla T, Elez E, Alsina M, Capdevila J, Perez-Garcia J, Sánchez-Ollé G, Aura C, Prudkin L, Landolfi S, Hernández-Losa J, Vivancos A, Tabernero J.

Mol Cancer Ther. 2012 Sep;11(9):2062-71. doi: 10.1158/1535-7163.MCT-12-0290. Epub 2012 Jun 21.

46.

Panitumumab: a summary of clinical development in colorectal cancer and future directions.

Argiles G, Dienstmann R, Elez E, Tabernero J.

Future Oncol. 2012 Apr;8(4):373-89. doi: 10.2217/fon.12.20. Review.

PMID:
22515440
47.

Molecular prescreening to select patient population in early clinical trials.

Rodón J, Saura C, Dienstmann R, Vivancos A, Ramón y Cajal S, Baselga J, Tabernero J.

Nat Rev Clin Oncol. 2012 Apr 3;9(6):359-66. doi: 10.1038/nrclinonc.2012.48. Review.

PMID:
22473105
48.

Application of monoclonal antibodies as cancer therapy in solid tumors.

Dienstmann R, Markman B, Tabernero J.

Curr Clin Pharmacol. 2012 May;7(2):137-45. Review.

PMID:
22432839
49.

Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategies.

Dienstmann R, Rodon J, Tabernero J.

Am Soc Clin Oncol Educ Book. 2012:168-72. doi: 10.14694/EdBook_AM.2012.32.168.

50.

Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer.

Dienstmann R, De Dosso S, Felip E, Tabernero J.

Mol Oncol. 2012 Feb;6(1):15-26. doi: 10.1016/j.molonc.2011.11.009. Epub 2011 Dec 6. Review.

Supplemental Content

Loading ...
Support Center